The proliferation of enhancement technologies and pharmacological agents has perpetuated the view of American doctors and patients of medical care as a market commodity driven by what consumers want and are willing to pay for.
Mark T. Hughes, MD, MA and Bimal H. Ashar, MD, MBA
Physicians are urged to evaluate an asymptomatic patient's request for CT screening and use the opportunity to educate the patient and determine the course of action that is in the patient's best interest.
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.
This article asks whether the benefits of neuroelectronic devices that restore function outweigh their risks to the individual and society and whether we should move beyond therapy to enhance our capabilities by the use of such devices?
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.